KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bionano Genomics (BNGO) EBIT (2017 - 2025)

Historic EBIT for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to -$8.5 million.

  • Bionano Genomics' EBIT rose 8055.17% to -$8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$36.7 million, marking a year-over-year increase of 6859.35%. This contributed to the annual value of -$104.0 million for FY2024, which is 5169.09% up from last year.
  • Bionano Genomics' EBIT amounted to -$8.5 million in Q3 2025, which was up 8055.17% from -$7.8 million recorded in Q2 2025.
  • Bionano Genomics' 5-year EBIT high stood at -$7.8 million for Q2 2025, and its period low was -$113.2 million during Q3 2023.
  • Moreover, its 5-year median value for EBIT was -$28.8 million (2021), whereas its average is -$29.1 million.
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 25214.78% in 2023, then soared by 8055.17% in 2025.
  • Bionano Genomics' EBIT (Quarter) stood at -$28.8 million in 2021, then plummeted by 30.38% to -$37.5 million in 2022, then soared by 33.51% to -$25.0 million in 2023, then skyrocketed by 52.15% to -$11.9 million in 2024, then increased by 28.5% to -$8.5 million in 2025.
  • Its EBIT was -$8.5 million in Q3 2025, compared to -$7.8 million in Q2 2025 and -$8.5 million in Q1 2025.